1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) Hereditary haemochromatosis (haemochromatosis type 1).
1.2 OMIM# of the disease 235200.
1.3 Name of the analysed genes or DNA/chromosome segments HFE. 1
1.4 OMIM# of the gene(s) 235200.
1.5 RefSeq NM 139003.
Mutational spectrum
In European populations, the incidence of C282Y homozygosity in individuals diagnosed with hereditary haemochromatosis ranges from 52% to 96%, 2 with a stronger association seen in Northern European populations, in which the allele frequency is at its highest. Mediterranean and Southern European populations have low C282Y and H63D allele frequencies and a corresponding lower association with clinically diagnosed iron overload. 3, 4 Compound heterozygosity for C282Y and H63D is associated with up to a further 6% of European cases 2 and the remainder have either one or none of the above variants. More than 20 different candidate mutations in HFE associated with the condition have been described; however, their clinical significance and prevalence in different populations is not always known.
Analytical methods
A range of reliable analytical techniques is available for the molecular genetic diagnosis of hereditary haemochromatosis. The most common method for detection of C282Y and H63D remains PCR amplification followed by restriction enzyme digestion. Alternative approaches are available and several commercial suppliers have developed analytical kits.
Analytical validation
Internal validation by testing known mutations and external validation through national or international quality assurance schemes. The Hannover haemochromatosis screening pilot study 5 has validated several test characteristics (see point 2).
1.9 Estimated frequency of the disease in Europe (incidence at birth ('birth prevalence') or population prevalence) The prevalence of the C282Y allele in Europe varies from 1.3% in Italy 6,7 to 11.4% in Southern Ireland. 8 H63D has an allele frequency ranging between 10% and 20% in Europe. 6 Penetrance of risk genotypes is incomplete and is greater in males than in females. Absolute figures for penetrance are difficult to ascertain, owing to variations in individual study design relating to objective criteria for confirming a diagnosis of iron overload and potential ascertainment bias in individual study populations. However, with increasing age, the majority of C282Y homozygotes will manifest elevated iron indices, but only a small proportion of these (current best estimates indicate 1-2%) will develop significant clinical symptoms of iron overload. 9, 10 An estimated 50% of homozygous C282Y females will show evidence of iron accumulation, usually associated with slower progression to a disease state. 7
1.10 If applicable, prevalence in the ethnic group of investigated person C282Y exists in populations of European origin. H63D occurs throughout the world population, but is most common in Europe (see point 1.9).
Diagnostic setting
Comment: Predictive diagnostics only after age 18. 12 
TEST CHARACTERISTICS

Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if quantification can only be made case by case.
Greater than 99%. 12 
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
Approximately 1-2% for clinically significant iron overload. 9, 10 In the range of 20-50% for symptoms associated with haemochromatosis.
2.6
Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Greater than 99%.
Index case in that family had not been tested: 98%.
3. CLINICAL UTILITY 3.1 (Differential) diagnosis: The tested person is clinically affected (To be answered if in 1.10 'A' was marked) 3.1.1 Can a diagnosis be made other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient Liver biopsy carries a degree of risk to the patient and tends to be used in the context of prognosis rather than diagnosis. It may be omitted if supporting biochemical and genetic data indicating iron overload are available. It may be performed if the genetic diagnostic test does not explain the clinical presentation of the patient in the presence of elevated biochemical iron indices. In some circumstances liver biopsy of C282Y homozygotes may be warranted. 13 3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged? Available studies suggest that HFE genotyping is cost effective. 12 Costs will differ depending on the progression of the disease at diagnosis. An early genetically proven diagnosis may avoid later alternative and expensive diagnostics and/or management strategies. 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
The genetic diagnosis of haemochromatosis has clinical validity for both index cases and their relatives. Appropriate predictive genetic testing of family members should establish their risk for the condition. Additional benefits may be realised with regard to lifestyle planning. In the Hannover pilot study of haemochromatosis screening, 70% of participants mentioned that they had gained personal benefits from the study. 15 
